Plaque Thrombosis is Reduced by Attenuating Plaque Inflammation with Pioglitazone and is Evaluated by Fluorodeoxyglucose Positron Emission Tomography
Plaque Thrombosis is Reduced by Attenuating Plaque Inflammation with Pioglitazone and is Evaluated by Fluorodeoxyglucose Positron Emission Tomography
复制标题
DOI：
10.1111/1755-5922.12119
复制
发表时间：
2015-06-01
影响因子：
3.1
通讯作者：
Zhao, Quan-Ming
中科院分区：
文献类型：
--
作者：
Zhang, Ming-Duo;Zhao, Xue-Cheng;Zhao, Quan-Ming
吡格列酮在减少临床事件和斑块炎症负荷方面的有益作用之间的关系尚不清楚。本研究的目的是确定吡格列酮是否可以减少斑块血栓形成的发病率和减少斑块炎症是否是吡格列酮减少斑块thromboses.Methods和ResultsTherapeutic兔分为两组：动脉粥样硬化组（n=13）和吡格列酮组（n=10）。对家兔进行药理学触发以诱导血栓形成。血清炎症标志物、FDG摄取、巨噬细胞和新生血管染色检测动脉炎症。进行两次PET/CT扫描（基线和治疗后扫描）。测量斑块面积、巨噬细胞和新生血管，并将组织学切片与PET/CT扫描匹配。与动脉粥样硬化组相比，吡格列酮组的血清MMP-9和hsCRP较低。吡格列酮组的SUV均值显著降低（0.62 ± 0.21 vs. 0.55 ± 0.19，P=0.008），但动脉粥样硬化组的SUV均值升高（0.61 ± 0.15 vs. 0.91 ± 0.20，P
IntroductionThe relationship between the beneficial effects of pioglitazone in reducing clinical events and plaque inflammatory burden remains unknown. This study aimed to determine whether pioglitazone can reduce the number of plaque thrombosis incidences and whether decreasing plaque inflammation is the mechanism by which pioglitazone reduces plaque thromboses.Methods and Resultstherosclerotic rabbits were divided into two groups: the atherosclerosis group (n=13) and pioglitazone group (n=10). The rabbits underwent pharmacological triggering to induce thrombosis. Serum inflammatory markers, FDG uptake, macrophage, and neovessel staining detected arterial inflammation. PET/CT scans were performed twice (baseline and posttreatment scans). Plaque area, macrophages, and neovessels were measured and the histologic sections were matched with the PET/CT scans. Serum MMP-9 and hsCRP were lower in the pioglitazone group compared to the atherosclerosis group. The SUVmean significantly decreased in the pioglitazone group (0.620.21 vs. 0.55 +/- 0.19, P=0.008), but increased in the atherosclerosis group (0.61 +/- 0.15 vs. 0.91 +/- 0.20, P